drugset / Trial / NCT03112096
A Phase I [18F]THK-5351 Positron Emission Tomography Study in Healthy Subjects and Alzheimer's Disease
Non-randomizedParallel-groupSingle-blindDiagnostic
Summary
This is a study to evaluate biodistribution, pharmacokinetics and safety of \[18F\]THK-5351 positron emission computed tomography in Cognitively Healthy Subjects and Patients with Alzheimer's Disease.
Timeline
- Start
- 2017-05-17
- Primary completion
- 2018-08-31
- Completion
- 2018-08-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | [18F]THK-5351 | Diagnostic / imaging agent | — | Intravenous |